FDA goes a little easier on CMO Ben Venue

Ben Venue, the contract manufacturing arm of Boehringer Ingelheim, got a lighter sentence than expected in its consent decree with the FDA, as the agency is still allowing it to manufacture 100 drugs it considers "essential for patient care," looking to stave off possible shortages. The initial clampdown cited 483 failings with the company's Bedford, OH, manufacturing facility, including the cringe-worthy revelation that inspectors found a 10-gallon barrel of urine, presumably used by workers in lieu of proper restroom breaks. Story

Suggested Articles

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

After delisting from the New York Stock Exchange, WuXi AppTec has received regulatory approval to be listed in Shanghai.